National Institutes of Health, National Institute of Mental Health, Rockville, MD, USA.
Adv Neurobiol. 2024;40:3-44. doi: 10.1007/978-3-031-69491-2_1.
Biomarkers are critically important in the development of drugs, biologics, medical devices, and psychosocial interventions for psychiatric disorders. As the lead federal agency charged with setting and supporting the national agenda for mental health research, the National Institute of Mental Health (NIMH) funds a broad portfolio of basic, translational, and clinical research focused on identifying, developing, and validating biomarkers for serious mental illnesses and neurodevelopmental conditions. In psychiatric research over the past 10 years, there has been an intensive effort to identify biomarkers as potential tools to improve treatment options for individuals with mental health concerns and increase success in the development of novel interventions. This chapter highlights examples of biomarker technologies that have been utilized to advance understanding of the pathophysiology of psychiatric disorders and the development of novel therapeutics.
生物标志物在药物、生物制剂、医疗器械和精神障碍的心理社会干预措施的开发中至关重要。作为负责制定和支持国家精神卫生研究议程的主要联邦机构,国立精神卫生研究所(NIMH)资助了广泛的基础、转化和临床研究组合,专注于确定、开发和验证严重精神疾病和神经发育状况的生物标志物。在过去 10 年的精神科研究中,人们一直在努力寻找生物标志物作为潜在工具,以改善有心理健康问题的个人的治疗选择,并提高新干预措施的成功率。本章重点介绍了一些生物标志物技术的示例,这些技术被用于推进对精神障碍病理生理学的理解和新疗法的开发。